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The aim of this prospective l\tudy was to assess whether
norethisterone enantate can be recommended for use in
patients with premenstrual Syndrome (PMS) who also
require effective contraception.
The subjects were 20 patillnts with severe PMS who
required effective contracePtiol1. Premenstrual symptom
scores on norethisterone enllntate and oral contraceptives
were compared.
Significantly fewer and less severe symptoms were
experienced by patients on hOrethisterone enantate than
those on oral contraceptive~. Norethisterone enantate can
therefore be recommended lor use in patients with PMS
who also require effective Cl:lntraception.
SAfrMedJ 1995; 85; 851-852.
The aetiology of premenstruql syndrome (PMS) is unclear.
Several theories exist and several agents have been
advocated for its treatment. Most of these agents have not
proved to be significantly better than placebo in double-
blind controlled trials. ' ,2
It is known, however, that the symptoms of PMS do not
occur during pregnancy or after menopause. There is a
growing acceptance that PMS is a function of cyclical
ovarian activity.3 Alteration of this cycle through the use of
anovulatory doses of subcut~neousoestradiol·implants' and
oestradiol patchess have been shown to be superior to
placebo. However, when cyclicql progesterone was added,
some of the symptoms of PMS recurred.'
Norethisterone enantate is a depot progesterone injection
used for hormonal contracePtion. Although its main actions
are to impair sperm movement into the uterine cavity by
alteration of the cervical mucus and to render the
endometrium unsuitable for I')idation by the production of
morphological changes, OVUlation is also suppressed by the
antigonadotrophic effects of· high plasma levels of
norethisterone, particularly during the first 5 - 7 weeks after
injection.
This study was conducted to ascertain whether these
changes in cyclical ovarian &etiVity would result in a
reduction of PMS symptoms,
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Methods
Twenty patients who were using combination oral
contraceptives and still complained of severe premenstrual
symptoms were entered into the trial if they fulfilled the
criteria outlined by Magos.' A prospective daily symptom
diary was kept by the patients for 2 months. The five worst
symptoms were listed and scored 0 - 3 according to
severity. The total symptom score of the premenstrual week
was compared with that of the postmenstrual week. PMS
was diagnosed if the premenstrual score was more than
double the postmenstrual score and the difference between
the scores was greater than 10.
Patients were then given 200 mg norethisterone enantate
by intramuscular injection and the oral contraceptive was
stopped. The prospective daily symptom diary was kept for
a further 2 months, and the symptom score of the
premenstrual week on the oral contraceptive was compared
with that on norethisterone enantate.
The study was approved by the Ethics Committee of the
University of Cape Town and patients gave informed
consent. Because of the effects of the depot progesterone
on the menstrual cycle, a double-blind trial was not
possible.
Results
The symptom scores of the 20 patients while on the oral
contraceptive and on norethisterone enantate are shown in
Table I. Because symptom scoring was subjective, the
differences between the two treatment groups were
analysed by means of the Kruskal-Wallis test.
Table I. Premenstrual symptom scores on an oral contraceptive
compared with norethisterone enantate
Discussion
Many patients with premenstrual symptoms are treated with
multiple agents, most of which are empirical or have only a
theoretical basis for their use." This is not only extremely
expensive, but many patients only improve for the first few
months, after which their symptoms recur. Since PMS is
associated with cyclical ovarian activity, blocking ovulation is
a logical way to reduce symptoms."
This can be achieved by oestrogens alone but patients
with an intact endometrium require cyclical progesterone.to
prevent endometrial hyperplasia if treated with oestradioJ
implants. This has, however, resulted in a partial return' of
their PMS symptoms.3 Norethisterone enantate 200 mg as
an a-weekly intramuscular injection is inexpensive, easy to
administer and effective in the management of PMS.
Because of the placebo effect, which has been .
extensively reported in trials involving PMS patients}-a
double-blind trial of norethisterone enantate versus"placebo
would be ideal. This would, however, exclude the m9ny PMS
patients who require reliable contraception. Furthermore, the
alteration in the menstrual cycle, which occurs when long-
acting progesterone injections are used, would make such a
trial impossible.
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In the 12 months since this trial was completed, the patients
were maintained on norethisterone enantate as follows.
The 9 patients whose symptom scores' had been reduced
to below 10 were continued on a-weekly injections and all
maintained their premenstrual score at below 10.
The 11 patients whose premenstrual scores were over
10 had the interval between injections reduced to 6 weeks.
In 9 of the 11 patients, amenorrhoea and total cessation of
symptoms occurred, In the remaining 2 patients, irregular
periods persisted but their .symptom scores were reduced to
below 10.
In summary, all 20 patients treated with norethisterone
enantate 200 mg every 6 - a weeks for 12 or more months,
maintained their premenstruc;li symptom scores at below 10.
Significantly fewer and less severe symptoms were
experienced by the patients on norethisterone enantate than
by those on an oral contraceptive (P < 0,005).
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